既往放疗对帕博利珠单抗治疗非小细胞肺癌临床活性与毒性的影响:KEYNOTE-001 1期试验的二次分析
该二次分析基于1期KEYNOTE-001试验中单中心98例晚期非小细胞肺癌患者,比较既往接受放疗与未接受放疗者接受帕博利珠单抗后的疗效与肺毒性。既往任何放疗者无进展生存期和总生存期均显著长于无既往放疗者,既往胸部放疗者任何记录肺毒性发生率高于无胸部放疗者,但治疗相关3级及以上肺毒性两组相似。作者认为既往放疗与更长的生存相关且安全性可接受,需进一步临床试验探讨联合策略。
要点
- 既往任何放疗者帕博利珠单抗中位无进展生存期4.4个月 vs 无放疗者2.1个月(HR 0.56)。
- 既往任何放疗者中位总生存期10.7个月 vs 无放疗者5.3个月(HR 0.58)。
- 既往胸部放疗者任何记录肺毒性63% vs 无胸部放疗者40%,3级及以上治疗相关肺毒性两组各1例。
核心结论
- 作者认为晚期NSCLC患者既往接受放疗后使用帕博利珠单抗,无进展生存期和总生存期长于无既往放疗者,且安全性可接受。
- 作者指出需进一步临床试验研究该联合方案,以确定晚期NSCLC患者的最佳治疗策略。
研究设计与样本
- 1期KEYNOTE-001试验的二次分析,单中心(美国加州大学洛杉矶分校)纳入98例晚期NSCLC患者。
- 患者年龄18岁及以上,ECOG体能状态1分及以下,器官功能充足,无肺炎病史。
- 帕博利珠单抗给药方案为2 mg/kg每3周、10 mg/kg每3周或10 mg/kg每2周,直至疾病进展、不可接受毒性或其他方案规定原因停药。
- 疗效与肺毒性分别采用免疫相关疗效评价标准与不良事件通用术语标准4.0版前瞻性评估。
- 主要目的是在意向治疗人群中判断既往放疗是否影响无进展生存期、总生存期和肺毒性。
主要发现
- 2012年5月22日至2014年7月11日入组98例并接受第一周期帕博利珠单抗,1例失访;97例中42例(43%)既往接受过任何放疗,38例(39%)接受过颅外放疗,24例(25%)接受过胸部放疗。
- 存活患者中位随访32.5个月(IQR 29.8-34.1)。
- 既往任何放疗者 vs 无既往放疗者:中位无进展生存期4.4个月(95%CI 2.1-8.6)vs 2.1个月(95%CI 1.6-2.3),HR 0.56(95%CI 0.34-0.91),p=0.019。
- 既往任何放疗者 vs 无既往放疗者:中位总生存期10.7个月(95%CI 6.5-18.9)vs 5.3个月(95%CI 2.7-7.7),HR 0.58(95%CI 0.36-0.94),p=0.026。
- 既往胸部放疗者24例中15例(63%)有记录的肺毒性 vs 无胸部放疗者73例中29例(40%);治疗相关肺毒性分别为3例(13%)vs 1例(1%),3级及以上治疗相关肺毒性两组各1例。
关键数值与推荐
- 既往任何放疗者 vs 无既往放疗者:中位无进展生存期4.4个月(95%CI 2.1-8.6)vs 2.1个月(95%CI 1.6-2.3),HR 0.56(95%CI 0.34-0.91),p=0.019。
- 既往任何放疗者 vs 无既往放疗者:中位总生存期10.7个月(95%CI 6.5-18.9)vs 5.3个月(95%CI 2.7-7.7),HR 0.58(95%CI 0.36-0.94),p=0.026。
- 既往颅外放疗者 vs 无既往颅外放疗者:中位无进展生存期6.3个月(95%CI 2.1-10.4)vs 2.0个月(95%CI 1.8-2.1),HR 0.50(95%CI 0.30-0.84),p=0.0084。
- 既往颅外放疗者 vs 无既往颅外放疗者:中位总生存期11.6个月(95%CI 6.5-20.5)vs 5.3个月(95%CI 3.0-8.5),HR 0.59(95%CI 0.36-0.96),p=0.034。
- 胸部放疗者任何记录肺毒性15/24(63%)vs 无胸部放疗者29/73(40%);治疗相关肺毒性3/24(13%)vs 1/73(1%),3级及以上治疗相关肺毒性两组各1例。
临床怎么用
- 作者认为晚期NSCLC患者既往放疗后使用帕博利珠单抗的生存优于无既往放疗者,安全性可接受。
- 作者建议需进一步临床试验研究放疗与帕博利珠单抗联合,以确定晚期NSCLC的最佳治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab. METHODS: We assessed patients with advanced NSCLC treated on the phase 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA). Patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ function, and no history of pneumonitis. Patients received pembrolizumab at a dose of either 2 mg/kg of bodyweight or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks, until disease progression, unacceptable toxicity, or other protocol-defined reasons for discontinuation. Disease response and pulmonary toxicity were prospectively assessed by Immune-related Response Criteria and Common Terminology Criteria for Adverse Events version 4.0. The primary objective of the KEYNOTE-001 trial was to assess the safety, side-effect profile, and antitumour activity of pembrolizumab. For our secondary analysis, patients were divided into subgroups to compare patients who previously received radiotherapy with patients who had not. Our primary objective was to determine whether previous radiotherapy affected progression-free survival, overall survival, and pulmonary toxicity in the intention-to-treat population. The KEYNOTE-001 trial was registered with ClinicalTrials.gov, number NCT01295827. FINDINGS: Between May 22, 2012, and July 11, 2014, 98 patients were enrolled and received their first cycle of pembrolizumab. One patient was lost to follow-up. 42 (43%) of 97 patients had previously received any radiotherapy for the treatment of NSCLC before the first cycle of pembrolizumab. 38 (39%) of 97 patients received extracranial radiotherapy and 24 (25%) of 97 patients received thoracic radiotherapy. Median follow-up for surviving patients was 32·5 months (IQR 29·8-34·1). Progression-free survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (hazard ratio [HR] 0·56 [95% CI 0·34-0·91], p=0·019; median progression-free survival 4·4 months [95% CI 2·1-8·6] vs 2·1 months [1·6-2·3]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (HR 0·50 [0·30-0·84], p=0·0084; median progression-free survival 6·3 months [95% CI 2·1-10·4] vs 2·0 months [1·8-2·1]). Overall survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (HR 0·58 [95% CI 0·36-0·94], p=0·026; median overall survival 10·7 months [95% CI 6·5-18·9] vs 5·3 months [2·7-7·7]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (0·59 [95% CI 0·36-0·96], p=0·034; median overall survival 11·6 months [95% CI 6·5-20·5] vs 5·3 months [3·0-8·5]). 15 (63%) of 24 patients who had previously received thoracic radiotherapy had any recorded pulmonary toxicity versus 29 (40%) of 73 patients with no previous thoracic radiotherapy. Three (13%) patients with previous thoracic radiotherapy had treatment-related pulmonary toxicity compared with one (1%) of those without; frequency of grade 3 or worse treatment-related pulmonary toxicities was similar (one patient in each group). INTERPRETATION: Our data suggest that previous treatment with radiotherapy in patients with advanced NSCLC results in longer progression-free survival and overall survival with pembrolizumab treatment than that seen in patients who did not have previous radiotherapy, with an acceptable safety profile. Further clinical trials investigating this combination are needed to determine the optimal treatment strategy for patients with advanced NSCLC. FUNDING: US National Institutes of Health.
引用
- Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017. PMID: 28551359. doi:10.1016/S1470-2045(17)30380-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。